The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

Joseph J Petraitis

Douglas G Batt

Donald J Pinto

Susan R Sherk

William John Pitts

Michael J Orwat

Prabhakar Kondaji Jadhav

This invention relates to ortho substituted phenyl compounds as inhibitors of prostaglandin synthase, to pharmaceutical compositions comprising such compounds and to methods of using such compounds as antiinflammatory and antipyretic agents. The class of compounds useful in this method of treatment is represented by Formula I below: ##STR1##

Prostaglandin synthase inhibitors

This invention relates to novel heterocycles including 3-�1-�3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzylo xycarbonylamino)propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to 2-carbocyclic and 2-heterocyclic quinoline-4-carbocyclic acid compounds, and salts thereof, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, and chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, in a mammal.

2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts

The present invention relates to substituted 2, 5-diaryl-4-isothiazolin-3-ones, pharmaceutical preparations containing them, and their use in the treatment of, thrombosis and, especially inflammation.

Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and

The invention relates to benzylindane phospholipase A.sub.2 inhibitors, pharmaceutical compositions containing them, and methods of treating phospholipase A.sub.2 -mediated conditions in mammals by administration of a therapeutically effective amount of such a benzylindane phospholipase A.sub.2 inhibitor including the representative example: ##STR1##

Substituted 1-benzylindanes and their use as inhibitors of phospholipase

(Benzimidazol-1'-ymethyl)phenylacetaldehydes as Topical Anti-inflammatories.

(N-benzyl) acetaldehyde bicyclic heterocycles useful as topical

(Indazol-1'-ymethyl)phenylacetaldehydes as Topical Anti-inflammatories.

This invention relates to substituted naphthofurans as anti-inflammatory and anti-allergic agents, pharmaceutical compositions containing them, processes for their preparation, and their use as anti-inflammatory and anti-allergic agents. The naphthofurans are of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sup.1 is CN or COOR.sup.9 ;

Substituted naphthofurans as anti-inflammatory agents

(Indol-1'-ylmethyl)-, (Indazol-1'-ylmethyl)-, (Benzimidazol-1'-ylmethyl)-, and (Benzotriazol-1'-ylmethyl)- phenylacetaldehydes as Topical Antiinflammatories.

Growing community of inventors

Glenmoore, PA, United States of America

Joseph J Petraitis